相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
Toru Mukohara et al.
CANCER SCIENCE (2010)
Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications
Stephen M. Keefe et al.
CLINICAL CANCER RESEARCH (2010)
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Randa M. Abdulrahman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma
Dale R. Shepard et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma
Ingrid Alexandre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule
Astrid A. M. van der Veldt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
I. Tamaskar et al.
ANNALS OF ONCOLOGY (2008)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib
Doru T. Alexandrescu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe et al.
LANCET ONCOLOGY (2007)
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging
Lisa J. Wilmes et al.
MAGNETIC RESONANCE IMAGING (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors -: a novel antiproliferative/antiangiogenic strategy in thyroid cancer
S. Hoffmann et al.
LANGENBECKS ARCHIVES OF SURGERY (2006)
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
FJ Giles et al.
LEUKEMIA RESEARCH (2006)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
